According to current guidelines, almost all authors decided not to change multi-modality treatment and not to adopt induction strategies to delay radiotherapy in mutation-positive [epidermal growth factor receptor (EGFR) mutations or anaplastic lymphoma kinase (ALK) traslocation] lung cancer patients [16]. Here, EGFR is linked to lung cancer.